BACKGROUND Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mitigate these conflicts are still limited. MAIN BODY The authors outline the possible benefits and ethical concerns that can result from financial interactions between biomedical companies and PAOs. They argue that the use of novel strategies, such as the creation of a standing ethics committee, could be helpful in managing FCOIs and ensuring the warranted trust of PAO's constituents. Although ethics committees to address FCOIs are common in the academic context, its use by PAOs is still limited. The authors conclude by describing the process of development and implementation of such an ethics committee at the Crohn's & Colitis Foundation. CONCLUSIONS While collaborations with industry can result in conflicts of interest, PAOs can develop strategies to address those conflicts. One such strategy is the creation of a standing independent ethics committee to guide PAOs on new and/or existing programs and protocols as they pertain to their industry relationships.

中文翻译：

---

当耐心倡导组织与行业见面时：一种处理财务利益冲突的新颖方法。

背景技术与学术界-产业界的合作伙伴关系一样，近年来，患者倡导组织（PAO）的行业财务支持已变得非常普遍。尽管近年来PAO与行业之间的金融利益冲突（FCOI）受到了越来越多的关注，但是缓解这些冲突的有效措施仍然有限。主要机构作者概述了生物医学公司与PAO之间的财务往来可能带来的好处和道德上的顾虑。他们认为，采用新颖的策略，例如成立常设道德委员会，可能对管理FCOI和确保PAO成员的应有信任有帮助。尽管解决FCOI的伦理委员会在学术界很常见，但PAO对其使用仍然有限。作者在最后总结了克罗恩与结肠炎基金会这样一个道德委员会的制定和实施过程。结论虽然与行业的合作可能会导致利益冲突，但PAO可以制定解决这些冲突的策略。一种这样的策略是建立一个常设的独立道德委员会，以指导PAO在与他们的行业关系有关的新的和/或现有的程序和协议上进行指导。